Other examples of available anticancer agents that have been identified to exhibit potent anti-glioma effect at preclinical level include plicamycin an antineoplastic antibiotic agent [148,151], trametinib a MEK inhibitor [152,153], afatinib an EGFR inhibitor and topotecan a topoisomerase-I inhibitor [105]. The gene discussed is EGFR; the disease is central nervous system cancer.